BMS-986214

**BMS-986214** is an investigational fixed-ratio combination of the immune-checkpoint monoclonal antibodies nivolumab and ipilimumab, co-formulated at a 1:3 nivolumab:ipilimumab ratio. It blocks programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4, releasing inhibitory checkpoints on antitumor T-cell responses. The product was designed as a single-vial intravenous infusion to simplify administration relative to sequential Opdivo and Yervoy infusions, and was evaluated in the Phase IIIb CheckMate 742 study in previously untreated unresectable or metastatic melanoma. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/66/NCT02905266/Prot_002.pdf))

Other names

nivolumab + ipilimumab fixed-ratio combinationnivolumab + ipilimumab FRCnivolumab/ipilimumab 1:3 fixed-ratio combination